ES8802621A1 - Un procedimiento para preparar un anticuerpo monoclonal hu- mano - Google Patents

Un procedimiento para preparar un anticuerpo monoclonal hu- mano

Info

Publication number
ES8802621A1
ES8802621A1 ES539987A ES539987A ES8802621A1 ES 8802621 A1 ES8802621 A1 ES 8802621A1 ES 539987 A ES539987 A ES 539987A ES 539987 A ES539987 A ES 539987A ES 8802621 A1 ES8802621 A1 ES 8802621A1
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
specific monoclonal
tumor specific
relates
diagnostic procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES539987A
Other languages
English (en)
Other versions
ES539987A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western Atlas Inc
Original Assignee
Litton Bionetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24300700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8802621(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Litton Bionetics Inc filed Critical Litton Bionetics Inc
Publication of ES8802621A1 publication Critical patent/ES8802621A1/es
Publication of ES539987A0 publication Critical patent/ES539987A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

CONSISTE EN EL CULTIVO DE HIBRIDOMAS O LINEAS DE CELULAS B TRANSFORMADAS, PROCEDENTES DE PACIENTES CANCEROSOS INMUNIZADOS ACTIVAMENTE CON ANTIGENO DE TUMOR ANTOLOGO, QUE PRODUCEN UN ANTICUERPO MONOCLONAL HUMANO. ESTE ANTICUERPO ES REACTIVO CON ANTIGENOS ESPECIFICOS PARA TUMORES, QUE INDUCIRAN UNA RESPUESTA INMUNE EN PACIENTES CON CANCERES DETERMINADOS. EL CULTIVO DE CELULAS TENDRA LUGAR EN UN MEDIO ADECUADO, 35-38GX, EN EQUILIBRIO CON UNA MEZCLA DE CO2 Y OXIGENO, DURANTE UN PERIODO DE TIEMPO SUFICIENTE PARA LA ACUMULACION Y AISLAMIENTO DE ANTICUERPOS DEL MEDIO DE CULTIVO POR METODOS TALES COMO: CROMATOGRAFIA, ULTRAFILTRACION Y CENTRIFUGACION A ALTA VELOCIDAD. LOS ANTICUERPOS ASI OBTENIDOS, PUEDEN EMPLEARSE TANTO EN TERAPIA COMO EN DIAGNOSTICO.
ES539987A 1984-01-31 1985-01-30 Un procedimiento para preparar un anticuerpo monoclonal hu- mano Expired ES8802621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57553384A 1984-01-31 1984-01-31

Publications (2)

Publication Number Publication Date
ES8802621A1 true ES8802621A1 (es) 1988-09-16
ES539987A0 ES539987A0 (es) 1988-09-16

Family

ID=24300700

Family Applications (1)

Application Number Title Priority Date Filing Date
ES539987A Expired ES8802621A1 (es) 1984-01-31 1985-01-30 Un procedimiento para preparar un anticuerpo monoclonal hu- mano

Country Status (15)

Country Link
EP (1) EP0151030B1 (es)
JP (2) JPH0759518B2 (es)
AT (1) ATE71410T1 (es)
AU (2) AU589351B2 (es)
CA (1) CA1340781C (es)
DE (1) DE3585093D1 (es)
DK (1) DK171896B1 (es)
ES (1) ES8802621A1 (es)
GR (1) GR850179B (es)
HU (1) HU209519B (es)
IE (1) IE58859B1 (es)
IL (1) IL74156A (es)
NZ (1) NZ210867A (es)
PT (1) PT79894B (es)
ZA (1) ZA85689B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3319751A1 (de) * 1983-05-31 1984-12-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren zur gewinnung von gegen tumorantigene gerichteten monoklonalen antikoerpern und diese enthaltende arzneimittel
DE3629640A1 (de) * 1986-08-30 1988-03-03 Behringwerke Ag Verwendung monoklonaler antikoerper zur therapie von tumoren
US6294172B1 (en) 1983-08-12 2001-09-25 Dade Behring Marburg Gmbh Monoclonal antibodies with specificity for membrane-associated antigens
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
JPS6283898A (ja) * 1985-10-09 1987-04-17 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺腺癌特異的単クロ−ン性抗体
US5552291A (en) * 1985-10-09 1996-09-03 Kyowa, Hakko Kogyo Co., Ltd. Anti-human pulmonary adenocarcinoma specific monoclonal antibody
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
JPS62207298A (ja) * 1986-03-06 1987-09-11 Kyowa Hakko Kogyo Co Ltd 抗ヒト胃癌単クロ−ン性抗体
JPH06100843B2 (ja) * 1986-06-23 1994-12-12 キヤノン株式会社 絶縁性磁性乾式現像剤
EP0265156A3 (en) * 1986-10-14 1990-08-29 Bunge (Australia) Proprietary Limited Monoclonal antibodies
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
HU213222B (en) * 1987-07-02 1997-03-28 Akzo Nv Method for producing of tumor antigen recognized by monoclonal antibody, antibody directed against antigen anp antibody specific to antiidiotypic antigen
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
AU629367B2 (en) * 1989-06-19 1992-10-01 Akzo N.V. Radioimmunotherapy using alpha-particles emission
EP0537168B1 (en) * 1990-04-12 1996-05-15 Akzo Nobel N.V. Ctaa 28a32, the antigen recognized by mca 28a32
WO1992000763A1 (en) * 1990-07-03 1992-01-23 Akzo N.V. Immunoreactive compound
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
JPH06508028A (ja) * 1991-05-16 1994-09-14 アクゾ・エヌ・ヴエー 腫瘍に関連するモノクローナル抗体８１ａｖ７８
IL103758A (en) * 1991-12-13 1998-07-15 Akzo Nv Cancer-specific monoclonal antibodies
JPH06113831A (ja) * 1992-04-08 1994-04-26 Dev Center For Biotechnol ハイブリドーマおよびその抗体
EP0650735A3 (en) * 1993-07-09 1999-04-14 Akzo Nobel N.V. Kit and method for pretargeting
JP2006507214A (ja) 2002-02-22 2006-03-02 イントラセル・リソーシーズ・エル・エル・シー 無菌の、免疫原性の、非腫瘍形成性の腫瘍細胞組成物及び方法
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
CN106133521A (zh) * 2013-10-02 2016-11-16 苏瑞科技有限公司 用于治疗异质肿瘤的病患特异性的免疫疗法
EP3409297A1 (en) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4322879A (en) * 1978-01-11 1979-07-19 Massachusetts General Hospital, The Producing antibodies
DE3211356A1 (de) * 1982-03-27 1983-09-29 Behringwerke Ag, 3550 Marburg Zell-hybrid, verfahren zu seiner herstellung sowie seine verwendung
JPS58201994A (ja) * 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
JPS59137497A (ja) * 1983-01-20 1984-08-07 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・カリフオルニア 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells

Also Published As

Publication number Publication date
AU3799285A (en) 1985-08-08
HU209519B (en) 1994-06-28
JPS60260597A (ja) 1985-12-23
EP0151030A3 (en) 1987-11-25
GR850179B (es) 1985-05-23
DE3585093D1 (de) 1992-02-20
EP0151030A2 (en) 1985-08-07
ATE71410T1 (de) 1992-01-15
IL74156A0 (en) 1985-04-30
DK40885D0 (da) 1985-01-30
JP2516731B2 (ja) 1996-07-24
EP0151030B1 (en) 1992-01-08
DK171896B1 (da) 1997-08-04
JPH06315395A (ja) 1994-11-15
IE850192L (en) 1985-07-31
AU589351B2 (en) 1989-10-12
IL74156A (en) 1990-08-31
CA1340781C (en) 1999-10-12
DK40885A (da) 1985-10-25
AU4736789A (en) 1990-05-03
NZ210867A (en) 1989-01-06
PT79894B (en) 1986-10-23
ES539987A0 (es) 1988-09-16
AU635511B2 (en) 1993-03-25
IE58859B1 (en) 1993-11-17
PT79894A (en) 1985-02-01
JPH0759518B2 (ja) 1995-06-28
HUT36859A (en) 1985-10-28
ZA85689B (en) 1986-04-30

Similar Documents

Publication Publication Date Title
ES8802621A1 (es) Un procedimiento para preparar un anticuerpo monoclonal hu- mano
ZA833686B (en) Human human hybridomas for cervical carcinoma
IL80231A (en) Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors
MX9705349A (es) Anticuerpo monoclonal 1a7 y su uso para el tratamiento de melanona y carcinoma de celulas pequeñas.
EP0256714A3 (en) Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2
EP0265500A4 (en) ANTIBODIES AGAINST HUMAN PROGESTERONE RECEPTOR AND DIAGNOSTIC PRODUCTS AND METHOD.
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
ATE71225T1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.
IL86958A0 (en) Human monoclonal antibody igm 16-88,cell lines producing it and antigen recognized thereby
EP0440689A4 (en) Anti-idiotypic antibody induction of antitumor response
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32
FI935038A0 (fi) Tumoer associerad monoklonal antikropp 81AV78
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
ZA878077B (en) Murine hybridoma lym-2 and diagnostic antibody produced thereby
BG50103A1 (en) Hybridome cell line, secretting monoclonal antibody against antigene determinante noc- 2 of malignant melanom in human

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20040601